Alector, Inc. (ALEC): Price and Financial Metrics
GET POWR RATINGS... FREE!
ALEC Stock Price Chart Interactive Chart >
ALEC Price/Volume Stats
| Current price | $9.20 | 52-week high | $43.32 |
| Prev. close | $8.89 | 52-week low | $7.50 |
| Day low | $8.77 | Volume | 505,100 |
| Day high | $9.27 | Avg. volume | 736,084 |
| 50-day MA | $11.27 | Dividend yield | N/A |
| 200-day MA | $18.50 | Market Cap | 766.61M |
Alector, Inc. (ALEC) Company Bio
Alector, Inc. operates as a clinical-stage biopharmaceutical company. It develops therapeutics for the treatment of neurodegenerative diseases including frontotemporal dementia (FTD), Alzheimer's disease, and Parkinson's disease. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA
Latest ALEC News From Around the Web
Below are the latest news stories about Alector Inc that investors may wish to consider to help them evaluate ALEC as an investment opportunity.
Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS DisordersSource: Company Summary Cyclerion Therapeutics (CYCN) is a spinoff from Ironwood Pharmaceuticals (IRWD) with several clinical failures over the last few years and a strong management team. This distressed situation creates an interesting investment opportunity pending clinical data for the company’s lead asset, CY6463. In 2019, under the pressure of... |
Homology Medicines: In Vivo Gene Therapy Platform With Delayed Lead Trial Coming Back OnlineSource: Company Summary Homology Medicines (FIXX) is a gene therapy and editing platform company centered around hematopoietic stem cells (“HSC”). The investment thesis for Homology builds on top of past analysis on Orchard Therapeutics (ORTX) to use HSCs to potentially cure immune-related disease - Orchard Therapeutics: For Immune-Related Disease (NASDAQ:ORTX)... |
ALEC Price Returns
| 1-mo | -4.17% |
| 3-mo | -41.92% |
| 6-mo | -55.45% |
| 1-year | -48.31% |
| 3-year | -46.97% |
| 5-year | N/A |
| YTD | -55.45% |
| 2021 | 36.48% |
| 2020 | -12.19% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...